From $MRNA 24 hours, it rose 5.7% to 148.98%, but the derivatives market was completely calm; the funding rate was zero, and open contracts were flat. The single source of this upswing was the positive Phase 3 cancer vaccine data mentioned by Stockanalysis, which is event-driven.
From a macro perspective, the global bond market is under pressure, and the high-interest-rate environment puts pressure on cash-flow-based valuations for biotech companies.
Trading tags: #TradFi #链上美股 #MRNA
Where do you think this assessment is most likely to be wrong?
From a macro perspective, the global bond market is under pressure, and the high-interest-rate environment puts pressure on cash-flow-based valuations for biotech companies.
Trading tags: #TradFi #链上美股 #MRNA
Where do you think this assessment is most likely to be wrong?